Business Context and Reporting Period
This Form 8-K Current Report from Zevra Therapeutics, Inc. (ZVRA) covers events occurring on November 26, 2025, with the report dated December 2, 2025. The filing primarily addresses changes to the Company's Board of Directors.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance changes.
Material Changes
- Director Resignation: Wendy Dixon resigned from the Board and all committees, effective December 2, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Alicia Secor was appointed as a Class I director, effective December 2, 2025. Her term expires at the 2028 annual meeting of stockholders.
- Committee Assignments: Ms. Secor has been appointed to the Compensation Committee and the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of material risks and contingencies. It notes that Ms. Secor will be compensated pursuant to the Company's Tenth Amended and Restated Non-Employee Director Compensation Policy and has entered into a standard indemnification agreement. No family relationships or undisclosed transactions involving Ms. Secor were identified.
Key Facts for Investor Verification
- Verify the effective date of the Board composition change (December 2, 2025).
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Confirm the terms of the Non-Employee Director Compensation Policy (Exhibit 10.1) to understand the financial implications of the new appointment.
- Note that this filing does not provide updated financial performance metrics; refer to the most recent 10-Q or 10-K for financial data.